Friday, June 11, 2004 - Diabetes Center
Rosuvastatin Label Change in EU Indicates Risk of Myopathy

June 10, 2004 — The U.S. Food and Drug Administration (FDA) issued a public health advisory yesterday, notifying healthcare professionals of labeling changes for rosuvastatin (Crestor, made by AstraZeneca) in the 22 member states of the European Union (EU). These changes, which are already in effect in FDA-approved labeling in the U.S., reflect the increased risk of myopathy associated with high levels of rosuvastatin.

Wednesday, June 09, 2004

Glucagon-like Peptide 1: Part II
The central role of GLP-1 in glucose tolerance has raised questions about the possible involvement of this peptide in the pathogenesis of diabetes. In addition, the wide range of coordinated actions by which GLP-1 lowers blood glucose has launched a new wave of drug development centered on this peptide hormone.

Incretin Hormones in Diabetes and Metabolism
The Incretin Effect
The Incretin Hormones: GIP and GLP-1
Incretin Physiology and Type 2 Diabetes Mellitus
Current Status of Drugs in Development
Concluding Remarks

Thursday, June 03, 2004

The Glycemic Index: "What is the Glycemic Index?
The glycemic index is a ranking of carbohydrates based on their immediate effect on blood glucose (blood sugar) levels. It compares foods gram for gram of carbohydrate. Carbohydrates that breakdown quickly during digestion have the highest glycemic indexes. The blood glucose response is fast and high. Carbohydrates that breakdown slowly, releasing glucose gradually into the blood stream, have low glycemic indexes."

Wednesday, June 02, 2004

ACE Inhibitors Improve Survival in Type 2 Diabetes: "May 27, 2004 � Angiotensin-converting enzyme (ACE) inhibitors significantly reduce all-cause mortality in patients with type 2 diabetes who do not have a history of cardiovascular disease, according to the results of a cohort study published in the June issue of Diabetes Care.
'ACE inhibitor therapy is widely used in lower-risk patients with type 2 diabetes to reduce mortality, despite limited evidence to support this clinical strategy,' write Dean T. Eurich, BSP, MSC, from the Institute of Health Economics in Edmonton, Alberta, Canada, and colleagues."